{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:13Z","timestamp":1753892053716,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Primary central nervous system lymphoma is an extremely aggressive type of non-Hodgkin lymphoma, and there is no consensus regarding the optimal management strategy for this disease. This study aimed to analyze the impact of consolidation therapy among young patients with intracranial primary diffuse large B-cell lymphoma (DLBCL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study analyzed the clinical data of 55 young patients (age &amp;lt; 60 years) with intracranial primary DLBCL who achieved complete remission (CR) after high-dose methotrexate (HD-MTX)-based chemotherapy from March 2001 to October 2021. Among these patients, 33 patients received consolidation therapy, and 22 patients did not. Overall survival (OS) and disease-free survival (DFS) were compared between the two groups via Kaplan\u2013Meier analysis, the multivariate Cox proportional hazards method, and propensity score matching (PSM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median follow-up time was 60.1 months. A total of 13 patients (23.6%) died, and 20 patients (36.4%) experienced recurrence. Patients who received consolidation therapy had higher 2-year OS (96.8% vs. 71.1%, <jats:italic>P<\/jats:italic> = 0.036) and DFS (90.9% vs. 56.4%, <jats:italic>P<\/jats:italic> = 0.006) rates than those without consolidation therapy. Multivariate analysis after PSM revealed that consolidation therapy was an independent predictor of DFS (HR = 0.282, 95% CI = 0.084\u20130.942, <jats:italic>P<\/jats:italic> = 0.040). Furthermore, rituximab was an independent predictor of favorable OS, and performance status was an independent predictor of OS and DFS. Subgroup analysis showed rituximab significantly improved OS in patients without consolidation therapy (88.9% vs. 45.0%, <jats:italic>P<\/jats:italic> = 0.006), but not in those with consolidation therapy (95.0% vs. 100%, <jats:italic>P<\/jats:italic> = 0.528).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Consolidation therapy improved DFS in young intracranial primary DLBCL patients achieving CR after HD-MTX-based chemotherapy. Autologous stem cell transplantation and radiotherapy showed comparable consolidation benefits. Good performance status correlated with favorable outcomes. Adding rituximab to induction chemotherapy may improve OS in patients without consolidation therapy, but it might be unnecessary for those eligible for consolidation. Further research involving a larger patient cohort is warranted to ascertain rituximab\u2019s efficacy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1493542","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T06:10:14Z","timestamp":1743401414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Consolidation therapy impact on survival outcomes in young patients with intracranial primary diffuse large B-cell lymphoma achieving complete remission: a propensity score matching analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Ge","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jijin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2022.05.01","article-title":"National guidelines for diagnosis and treatment of Malignant lymphoma 2022 in China","volume":"34","year":"2022","journal-title":"Chin J Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1002\/hem3.89","article-title":"Primary central nervous system lymphomas: EHA\u2013ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Ferreri","year":"2024","journal-title":"HemaSphere"},{"key":"B4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/diagnostics10121076","article-title":"Primary central nervous system lymphomas: a diagnostic overview of key histomorphologic, immunophenotypic, and genetic features","volume":"10","author":"Lauw","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: An LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000328","article-title":"Is autologous stem cell transplantation a safe and effective alternative to whole brain radiation as consolidation therapy in patients with primary central nervous system lymphoma?: a critically appraised topic","volume":"26","author":"Gritsch","year":"2021","journal-title":"Neurologist"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41598-020-80724-0","article-title":"High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials","volume":"11","author":"Yu","year":"2021","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad224","article-title":"Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105\/ALLG NHL 24 study","volume":"26","author":"Bromberg","year":"2024","journal-title":"Neuro Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2666","article-title":"Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis","volume":"37","author":"Schmitt","year":"2019","journal-title":"Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.06.008","article-title":"Role of rituximab in treatment of patients with primary central nervous system lymphoma (PCNSL): A systematic review and meta","volume":"23","author":"Zhang","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2014.06.011","article-title":"Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009","volume":"26","author":"Shibamoto","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.07.958","article-title":"Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group)","volume":"64","author":"O\u2019Brien","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001395","article-title":"Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma","volume":"84","author":"Korfel","year":"2015","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.6910","article-title":"Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma","volume":"24","author":"Gavrilovic","year":"2006","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23670","article-title":"Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy","volume":"113","author":"Ekenel","year":"2008","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-010-0497-x","article-title":"Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred","volume":"104","author":"Omuro","year":"2011","journal-title":"J Neurooncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00491","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study","volume":"40","author":"Houillier","year":"2022","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/hon.3083","article-title":"Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis","volume":"41","author":"Epperla","year":"2023","journal-title":"Hematological Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103341","article-title":"Prognostic models in primary central nervous system lymphoma patients: A systematic review","volume":"161","author":"Jelicic","year":"2021","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1493542\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T06:10:15Z","timestamp":1743401415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1493542\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":27,"alternative-id":["10.3389\/fonc.2025.1493542"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1493542","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"article-number":"1493542"}}